Drug General Information (ID: DDI7JARVYK)
  Drug Name Heparin Drug Info Cefazolin Drug Info
  Drug Type Small molecule Small molecule
  Therapeutic Class Anticoagulants Antibiotics
  Structure

 Mechanism of Heparin-Cefazolin Interaction (Severity Level: Minor)
     Increased risk of bleeding Click to Show/Hide Mechanism Graph
Could Not Find 2D Structure
      Drug Name Heparin Cefazolin
      Mechanism Risk of bleeding
Anticoagulant 
Risk of bleeding
Inhibit the growth of vitamin K-producing intestinal bacteria, inhibit the production of vitamin K-dependent coagulation factors via the methylsulfotetrazole side chain, and/or inhibit platelet activity 
      Key Mechanism Factor 1
Factor Name Bleeding
Factor Description Patients may be at risk for bleeding when the outcome of a disease or disease treatment confounds the standard mechanisms for maintaining hemostasis. Signs or symptoms of abnormal bleeding include: bleeding that takes a long time to stop (including nosebleeds, bleeding gums, bleeding from cuts and abrasions, and menstrual bleeding); severe unexplained bruising, or bruising that becomes larger; blood in the urine or stool, etc.
      Mechanism Description
  • Increased risk of bleeding by the combination of Heparin and Cefazolin 

Recommended Action
      Management Usually, no special management is necessary, but the patient should be monitored for bleeding if heparin must be given concurrently. Vitamin K is effective in treating cephalosporin-induced coagulopathies.

References
1 Khaleeli M, Giorgio AJ "Defective platelet function after cephalosporin administration." Blood 48 (1976): 791-2.[PMID: 974269]
2 Angaran DM, Dias VC, Arom KV, et al "The comparative influence of prophylactic antibiotics on the prothrombin response to warfarin in the postoperative prosthetic cardiac valve patient." Ann Surg 206 (1987): 155-61
3 Lerner PI, Lubin A "Coagulopathy with cefazolin in uremia." N Engl J Med 290 (1974): 1324